We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Heterogeneous Populations of Melanoma Circulating Tumor Cells Detected

By LabMedica International staff writers
Posted on 02 Mar 2020
Circulating tumor cells (CTCs) can be assessed through a minimally invasive blood sample with potential utility as a predictive, prognostic and pharmacodynamic biomarker. More...
The large heterogeneity of melanoma CTCs has hindered their detection and clinical application.

A new way to detect melanoma cells circulating in the blood has the potential to significantly improve the monitoring of cancer patients and guide future treatment. Two platforms for the isolation and purification of melanoma circulating tumor cells (CTCs) from patient blood samples have been compared.

An international team of scientists led by those at the Edith Cowan University (Perth, Australia) compared two microfluidic devices for the recovery of circulating melanoma cells. The presence of CTCs in 43 blood samples from patients with metastatic melanoma was evaluated using a combination of immunocytochemistry and transcript analyses of five genes by RT-PCR and 19 genes by droplet digital PCR (ddPCR), whereby a CTC score was calculated.

Circulating tumor DNA (ctDNA) from the same patient blood sample was assessed by ddPCR targeting tumor-specific mutations (Bio-Rad, Hercules, CA, USA). The two devices used were the Parsortix cell separation system (Angle, The Surrey Research Park, UK) and the ClearCell FX1 platform (Biolidics, Singapore).

Parsortix cell-sorting system uses microfluidic disposable cassettes to capture and harvest CTCs based on their less-deformable nature and larger size compared to other blood components. Captured cells can be fixed and stained for in-cassette identification and enumeration or can be recovered for external staining and molecular analysis with qPCR and other techniques. ClearCell FX1 system is a label-free liquid biopsy device that the firm says automates CTC isolation and enrichment and offers two different purity protocols. After lysing red blood cells in a blood sample, the platform passes the sample through its single-use CTChip FR1 microfluidic biochip to isolate CTCs from a white blood cell (WBC) background.

The team matched blood samples from 10 metastatic patients. Using immunostaining, the investigators saw that Parsortix produced, on average, a two-fold lower WBC background than produced by ClearCell. They detected CTCs in 30% of melanoma patient samples processed via both Parsortix (range of 1 to 13 CTCs) and ClearCell (range of 2 to 10 CTCs). Using RT-PCR, the group successfully detected at least one melanoma transcript in 40% and 60% of samples enriched by Parsortix and ClearCell, respectively. The study authors also found that ClearCell detected CTCs in samples that Parsortix did not identify and they noted that ClearCell-enriched fractions also showed a slightly higher abundance of detected transcripts compared to Parsortix-derived samples.

Comparing CTC fractions derived from 43 blood samples from the melanoma patients, the team detected CTCs via immunocytochemistry in 12 of the 43 samples. In addition, they saw that the CTCs varied in size, ranging from 10.2 µm to 68.3 µm. The study was published on February 10, 2020 in the British Journal of Cancer.

Related Links:
Edith Cowan University
Bio-Rad
Angle
Biolidics



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.